Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tzu‐Sheng Cheng"'
Autor:
Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, Ming‐Lung Yu
Publikováno v:
Cancer Medicine, Vol 11, Iss 1, Pp 104-116 (2022)
Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors
Externí odkaz:
https://doaj.org/article/8169183efd244c82bda9348fe3369e9a
Autor:
Tzu‐Sheng Cheng, Po‐Cheng Liang, Chung‐Feng Huang, Ming‐Lun Yeh, Ching‐I Huang, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Chia‐Yen Dai, Ping‐Hsin Hsieh, Wan‐Long Chuang, Ming‐Lung Yu
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 37, Iss 4, Pp 334-345 (2021)
Abstract Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including
Externí odkaz:
https://doaj.org/article/d04f3744ee2a453faa48c543e41a5205
Autor:
Tzu-Sheng Cheng, 鄭子盛
95
The purpose of this study is to conduct a case study on Organization C during the course of its corporatization. A proper set of proposals aim to corporatise the organization is also formulated under the consideration of organizational vision
The purpose of this study is to conduct a case study on Organization C during the course of its corporatization. A proper set of proposals aim to corporatise the organization is also formulated under the consideration of organizational vision
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/ba4vyu
Autor:
Ming-Lung Yu, Shinn-Cherng Chen, Wan-Long Chuang, Chung-Feng Huang, Zu-Yau Lin, Ming-Lun Yeh, Tzu-Sheng Cheng, Ping-Hsin Hsieh, Ching-I Huang, Chia-Yen Dai, Jee-Fu Huang, Po-Cheng Liang
Publikováno v:
Kaohsiung Journal of Medical Sciences, Vol 37, Iss 4, Pp 334-345 (2021)
Chronic hepatitis C (CHC) is a major cause of cirrhosis, hepatocellular carcinoma (HCC), and mortality. Eliminating hepatitis C virus (HCV) can greatly improve long‐term outcomes. Several direct‐acting antiviral agents (DAAs), including sofosbuvi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0931c8e1fafd60d7087e59b3ff13c13f
https://doaj.org/article/d04f3744ee2a453faa48c543e41a5205
https://doaj.org/article/d04f3744ee2a453faa48c543e41a5205